These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 23753231)

  • 61. DHPG (Gancyclovir) improves survival in CMV pneumonia.
    Mai M; Nery J; Sutker W; Husberg B; Klintmalm G; Gonwa T
    Transplant Proc; 1989 Feb; 21(1 Pt 2):2263-5. PubMed ID: 2540565
    [No Abstract]   [Full Text] [Related]  

  • 62. [Ganciclovir treatment failure in adult allogeneic hematopoietic stem cell transplant recipients with cytomegalovirus infection--a single centre experience].
    Vejražková E; Hubáček P; Kutová R; Plíšková L; Košťál M; Štěpánová V; Zavřelová A; Radocha J; Malá E; Žák P
    Epidemiol Mikrobiol Imunol; 2015 Sep; 64(3):160-8. PubMed ID: 26448304
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series.
    El Chaer F; Mori N; Shah D; Oliver N; Wang E; Jan A; Doan V; Tverdek F; Tayar J; Ariza-Heredia E; Chemaly RF
    Antiviral Res; 2016 Nov; 135():91-96. PubMed ID: 27594527
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ganciclovir and hyperimmunoglobulin for treating cytomegalovirus infection in bone marrow transplant recipients.
    Aulitzky WE; Tilg H; Niederwieser D; Hackl M; Meister B; Huber C
    J Infect Dis; 1988 Aug; 158(2):488-9. PubMed ID: 2841384
    [No Abstract]   [Full Text] [Related]  

  • 66. [Analysis of pathogenesis of pneumonia post allogeneic hematopoietic stem cell transplantation].
    Liu DH; Huang XJ; Guo NL; Xu LP; Chen H; Han W; Jiang Q; Liu KY; Lu DP
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Apr; 37(2):130-3. PubMed ID: 15841138
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Atypical presentation of CMV pneumonia in a heart transplant patient.
    Boussouar S; Campedel L; Noble PD; Turki MW; Calvo J; Pourcher V; Rolland-Debord C
    Med Mal Infect; 2018 Mar; 48(2):151-153. PubMed ID: 29329823
    [No Abstract]   [Full Text] [Related]  

  • 68. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients.
    Konoplev S; Champlin RE; Giralt S; Ueno NT; Khouri I; Raad I; Rolston K; Jacobson K; Tarrand J; Luna M; Nguyen Q; Whimbey E
    Bone Marrow Transplant; 2001 Apr; 27(8):877-81. PubMed ID: 11477447
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Treatment and Prevention of CMV Disease in Transplant Recipients: Current Knowledge and Future Perspectives.
    Hodowanec AC; Pikis A; Komatsu TE; Sampson MR; Younis IR; O'Rear JJ; Singer ME
    J Clin Pharmacol; 2019 Jun; 59(6):784-798. PubMed ID: 30586161
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.
    Green ML; Leisenring W; Stachel D; Pergam SA; Sandmaier BM; Wald A; Corey L; Boeckh M
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1687-99. PubMed ID: 22683614
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.
    Panagou E; Zakout G; Keshani J; Smith C; Irish D; Mackinnon S; Kottaridis P; Fielding A; Griffiths PD
    Transpl Infect Dis; 2016 Jun; 18(3):405-14. PubMed ID: 27061703
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Diagnostic yield of the cytomegalovirus (CMV) antigenemia assay and clinical features in solid organ transplant recipients and hematopoietic stem cell transplant recipients with CMV pneumonia.
    Moon SM; Sung H; Kim MN; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH
    Transpl Infect Dis; 2012 Apr; 14(2):192-7. PubMed ID: 22260384
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Persistent CMV infection after allogeneic hematopoietic stem cell transplantation in a CMV-seronegative donor-to-positive recipient constellation: Development of multidrug resistance in the absence of anti-viral cellular immunity.
    Herling M; Schröder L; Awerkiew S; Chakupurakal G; Holtick U; Kaiser R; Pfister H; Scheid C; Di Cristanziano V
    J Clin Virol; 2016 Jan; 74():57-60. PubMed ID: 26672492
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
    Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
    Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cytomegalovirus DNAemia detected with real-time polymerase chain reaction in hematopoietic stem cell transplant patients.
    Sahin DG; Gunduz E; Kasifoglu N; Akay OM; Us T; Gulbas Z
    Adv Ther; 2013 Aug; 30(8):784-91. PubMed ID: 23959787
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients].
    Li L; Wang Y; Yan CH; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):191-195. PubMed ID: 29518863
    [No Abstract]   [Full Text] [Related]  

  • 78. Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients.
    Camargo JF; Anderson AD; Rosa R; Kimble E; Komanduri KV; Morris MI
    Transpl Infect Dis; 2019 Apr; 21(2):e13054. PubMed ID: 30689300
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Diseases of the EBMT.
    Ljungman P; De Bock R; Cordonnier C; Einsele H; Engelhard D; Grundy J; Locasciulli A; Reusser P; Ribaud P
    Bone Marrow Transplant; 1993 Oct; 12(4):399-403. PubMed ID: 8275040
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Surveillance of CMV infection in allo-HSCT recipients and guidance on preemptive therapy by RQ-PCR.
    Li Y; Gao L; Wang LL; Ding Y; Xu YY; Li HH; Jing Y; Bo J; Huang WR; Wang QS; Gao CJ; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):161-8. PubMed ID: 23484712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.